Natco rode Revlimid to multi-year highs, but that one-time opportunity is tapering fast. With earnings set to plunge and valuation still pricey, investors await the next growth trigger.
Source :- mint – markets Read More
- Home
- Livemint Markets
Natco Pharma’s cyclical business model, low revenue visibility are bitter pills to swallow
- No Comments
- 6 Min Read
Share it :
Get free tips and resources right in your inbox, along with 10,000+ others
Categories
Latest Post
